Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

Acute Myeloid Leukemia in Children Clinical Trial

Official title: Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults

Status Recruiting

Clinical Trial Summary

Donor Lymphocyte Infusion (DLI) following salvage chemotherapy is the one of the most widely used treatment approaches in patients who relapse after allogeneic hematopoietic cell transplant (allo-HCT). However, the complete remission (CR) rates and long term survival remain very poor in these patients and, therefore, there is an unmet need to develop more effective treatment approaches in patients who relapse after allo-HCT.

Based on the initial promising results with our ongoing cytokine-induced memory-like (CIML) natural killer (NK) cell trial, the investigators hypothesize that combining the CIML NK cells with DLI approach will significantly enhance the graft versus leukemia and therefore potentially provide potentially curative therapy for these patients with otherwise extremely poor prognosis. Combining CIML NK cells with the DLI platform will also potentially allow these adoptively transferred cells to persist for longer duration as they should not be rejected by donor T cells as the CIML NK cells are derived from the same donor. The use of CIML NK cells is unlikely to lead to excessive graft versus host disease (GVHD) as previous studies have not been associated with excessive GVHD rates.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Acute Myeloid Leukemia in Children

• NCT number: NCT03068819
• Study type: Interventional
• Source: Washington University School of Medicine
• Contact: Amanda Cashen, M.D.
• Phone: 314-454-8323
• Email: acashen@wustl.edu
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 23, 2017
• Completion date: October 20, 2028